Real Life Use of Alemtuzumab, Cladribine, Dimethylfumarate, Fingolimod, Natalizumab, Ocrelizumab, Ofatumumab, Ozani?mod, Siponimod and Teriflunomide: Benefit-Risk Data from the Austrian Multiple Sclerosis Treatment Registry
- M Guger (Author)
- Enzinger, C. (Author)
- F Leutmezer (Author)
- F Di Pauli (Author)
- J Kraus (Author)
- T Berger (Author)
Activity: Talk, presentation or poster › Poster